Rigel Pharmaceuticals ($RIGL) Stock Hub 2026: Q2 Profitability, VEPPANU Launch and R289

01 Latest verified developments through August 28, 2026

VEPPANU is now on the market. The worldwide license became effective June 11 and Rigel paid $70 million upfront. On August 13, 2026 the company announced that VEPPANU is available by prescription in the United States and Puerto Rico, through its network of specialty distributors and specialty pharmacies, at a list price of $29,400 per 30-day supply. The deal adds an FDA-approved product and a new oncology market, but also royalties, milestones, transition funding and take-or-pay manufacturing obligations.

Two holders crossed into view in the middle of the month. Soleus Capital Master Fund reported 1,843,504 shares, 9.9% of the class, on a Schedule 13G/A filed August 13, and Armistice Capital with Steven Boyd reported 1,672,000 shares, 8.95%, on a Schedule 13G/A filed August 14. Both are positions as of June 30, 2026, so they describe the register at quarter-end rather than the register today.

R289 remains the main internally controlled clinical catalyst. The Phase 1b lower-risk MDS expansion is testing 500 mg once daily and 500 mg twice daily. Dose selection is guided for the second half and preliminary data by year-end.

International reach broadened. Knight launched TAVALISSE in Mexico and obtained Brazilian approval in May. Kissei filed the Japanese olutasidenib application in May, producing a $4 million milestone in Q2. No exact Japanese decision date has been publicly confirmed.

The portfolio is producing mixed commercial signals. TAVALISSE and REZLIDHIA grew in Q2; GAVRETO declined because of lower volume and higher revenue reserves, partly offset by price. That makes VEPPANU diversification strategically useful, but it raises the execution load on a company with a small market capitalization.

02 Executive summary

Rigel is no longer a development-stage biotech funded primarily by capital markets. It sells three approved medicines in the United States, earns supply and royalty revenue from international partners, generated positive operating cash flow in the first half of 2026, and is preparing a fourth U.S. launch. That commercial transformation is the strongest part of the thesis.

The concentration remains substantial. TAVALISSE generated $47.4 million, or about 71%, of Q2 net product sales. REZLIDHIA contributed $8.9 million and GAVRETO $10.7 million. VEPPANU had no Rigel revenue in the quarter. The company therefore has four brands operationally, but only one has yet demonstrated scale inside Rigel’s current income statement.

Q2 profitability was real, but historical headline comparisons require adjustment. The prior-year quarter included a $40 million non-cash release of a Lilly cost-share liability. Full-year 2025 EPS is also distorted by a $245.9 million non-cash deferred tax benefit. A trailing P/E near 2.4 is therefore not a clean valuation shortcut.

Liquidity is adequate for the current plan, not unlimited. June 30 cash and short-term investments totaled $95.3 million and debt was $40 million, for $55.3 million of quarter-end net cash. Rigel repaid $32 million in July, leaving $8 million drawn; that repayment reduces gross cash and debt together and does not by itself create new net cash. H1 operating cash flow was positive $33.4 million, while the $70.3 million intangible-asset payment reflects the VEPPANU acquisition.

The next value-creation test is two-dimensional. Commercially, VEPPANU must show that Rigel can compete in a crowded ESR1-mutated breast-cancer market after paying substantial licensing economics. Clinically, R289 must turn encouraging early transfusion-independence data from 18 evaluable patients at active doses into a reproducible dose-expansion signal.

03 What the company actually is today

Rigel has evolved into a specialty commercial organization that discovers some assets internally and acquires or licenses others. The common thread is not one scientific platform; it is a hematology/oncology sales, medical-affairs and business-development infrastructure used to operate narrow, biomarker-defined or specialist-treated brands.

04 Q2 and first-half financial quality

Gross product sales were $88.5 million and discounts/allowances were $21.4 million, producing $67.0 million of net sales. That is a roughly 24% gross-to-net deduction. The portfolio-level product gross margin implied by reported net product sales and cost of product sales was about 87%, but it should not be extrapolated mechanically: Rigel has benefited from zero-cost pre-approval TAVALISSE API inventory, and the 10-Q says future inventory will reflect full manufacturing cost.

Contract revenue is useful but uneven. Q2 included $5.8 million from Kissei, including a $4 million Japan filing milestone, $5.0 million from Grifols and $0.3 million from Medison. This is why the raised $30 million full-year contract-revenue guide should not be capitalized like recurring U.S. product demand.

Customer concentration is another quality issue. McKesson represented 46% of Q2 total revenue and Cencora 21%. These are distributors rather than end-market customers, but collection, purchasing patterns and channel inventory can still create quarter-to-quarter noise.

05 TAVALISSE: the cash engine and concentration risk

TAVALISSE is an oral SYK inhibitor approved for thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. It generated $47.4 million of Q2 sales, up 18%, and $84.7 million in the first half, up 24%. Management attributes H1 growth to volume, price and lower revenue reserves.

The economic role is larger than the U.S. sales line. Grifols, Kissei, Medison and Knight extend fostamatinib into international territories through supply, royalty and milestone structures. Q2 Grifols revenue included $3.0 million of supply and $2.0 million of royalties. Mexico launched and Brazil approved TAVALISSE in May 2026, but the cadence of ex-U.S. revenue remains partner dependent.

Competition is broad and changing. Physicians can use corticosteroids, IVIG, splenectomy, thrombopoietin-receptor agonists such as romiplostim, eltrombopag and avatrombopag, and now the oral BTK inhibitor WAYRILZ (rilzabrutinib), approved in August 2025 for adults with persistent or chronic ITP after insufficient response to previous treatment. TAVALISSE offers a differentiated SYK mechanism, but it does not own the treatment pathway.

The long-duration risk is patent competition. The FDA approved Annora’s fostamatinib ANDA on June 17, 2026, but regulatory approval is not the same as immediate commercial entry: Rigel’s settlement permits Annora to launch in the second quarter of 2032, or earlier only under specified circumstances. That is not a near-term cliff, but TAVALISSE’s current 71% share of product revenue makes life-cycle planning and portfolio diversification economically important well before 2032.

06 REZLIDHIA: smaller base, durable-response narrative

REZLIDHIA is approved for adults with relapsed or refractory AML carrying a susceptible IDH1 mutation. Q2 net sales were $8.9 million, up 27%, and H1 sales were $17.0 million, up 29%. The increase came from volume and price, partly offset by higher revenue reserves.

The registrational dataset produced a 35% complete-remission plus partial-hematologic-recovery rate. Five-year follow-up and 2026 conference analyses support a durable-response narrative, including long responses after prior venetoclax. At ASCO/EHA 2026, company-reported real-world chart data in post-venetoclax patients showed a 60.8% CR/CRh rate and 30.3-month median response duration, but those retrospective data should not be treated like a randomized comparison.

The direct IDH1 competitor is TIBSOVO (ivosidenib). There is no head-to-head randomized trial establishing superiority. REZLIDHIA also carries a boxed warning for differentiation syndrome and requires close hepatic monitoring; differentiation syndrome occurred in 16% and hepatotoxicity in 23% in the label dataset cited by Rigel.

Expansion work adds optionality but also cost. The MD Anderson collaboration evaluates combinations and earlier disease settings in AML and related myeloid cancers; Rigel can fund up to $15 million over five years and had paid $5.3 million through June. CONNECT’s TarGeT-D study evaluates olutasidenib with temozolomide and then maintenance monotherapy in IDH1-mutated high-grade glioma, with up to $3 million of Rigel funding.

Kissei submitted olutasidenib for approval in Japan in May 2026. The filing generated a $4 million milestone, but Forma receives a portion of sublicensing economics. A Japanese approval would validate geographic expansion; the timing and commercial magnitude remain open.

07 GAVRETO: proven efficacy, safety and share pressure

GAVRETO is a selective RET inhibitor. It has full U.S. approval for metastatic RET-fusion-positive NSCLC and accelerated approval for specified advanced or metastatic RET-fusion-positive thyroid cancer in adults and patients aged 12 and older. Q2 sales were $10.7 million, down 10%; H1 sales were $20.3 million, down 2%. The 10-Q attributes the decline to lower volume and higher revenue reserves, partly offset by price.

The final Phase 3 AcceleRET-Lung analysis met its primary PFS endpoint and showed higher response and more durable response than standard care. The safety result is the commercial counterweight: infections occurred in 72% of GAVRETO patients, Grade 3 in 18%, Grade 4 in 3.7%, and fatal in 7% in the updated safety information. The label now carries a boxed warning for serious infections, including opportunistic infections.

RETEVMO (selpercatinib) is the central competitor and has a broader age/solid-tumor label. The FDA granted traditional approval for its RET-fusion solid-tumor indication in July 2026. GAVRETO can compete on efficacy, physician experience and access, but the Q2 volume decline and boxed warning are reasons to demand evidence from prescriptions and net sales, not conference abstracts alone.

Rigel paid the final $5 million of the $15 million Blueprint purchase price in June. Blueprint remains eligible for up to $97.5 million of commercial milestones, $5 million of regulatory milestones and tiered royalties ranging from 10% to 30% on U.S. net sales. GAVRETO therefore diversifies revenue without being economically equivalent to a wholly owned asset.

08 VEPPANU: the approved PROTAC launch

VEPPANU is the first FDA-approved heterobifunctional protein degrader, or PROTAC. It is approved for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, identified by an FDA-authorized test, whose disease progressed after at least one line of endocrine therapy. Recommended dosing is 200 mg orally once daily with food.

The launch, and the number that comes with it

Rigel announced on August 13, 2026 that VEPPANU is available by prescription in the United States and Puerto Rico. The product is distributed through the company’s network of specialty distributors and specialty pharmacies, and the announced list price is $29,400 per 30-day supply.

What a list price does and does not tell you. It is the starting point of the gross-to-net calculation, not the revenue Rigel records. Rebates to payers, discounts in the 340B and Medicaid channels, copay assistance through the company’s own support programme and distributor fees are all deducted before net sales. In an oncology launch aimed at a genotype-selected second-line population, the size of the treated population is also gated by testing: a patient qualifies only where an FDA-authorised test has found an ESR1 mutation. Those two filters, net price and tested patients, matter more to the first four quarters of revenue than the list price on the announcement.

The company has kept VEPPANU outside its 2026 revenue guidance, so the launch quarter will be the first read on the commercial slope, and it will be visible in the third-quarter report rather than in any guidance revision before it.

In the ESR1-mutated population of VERITAC-2, median PFS was 5.0 months with vepdegestrant and 2.1 months with fulvestrant, with a hazard ratio of 0.57. Objective response was 19% versus 4%. Overall survival was immature at the analysis. These results establish clinical benefit versus fulvestrant in the studied population, not superiority to other approved oral endocrine agents.

The commercial field includes ORSERDU (elacestrant) and INLURIYO (imlunestrant), both approved in ESR1-mutated disease after endocrine therapy. Their trials used different controls, eligibility rules and assessment methods, so cross-trial median PFS should not be ranked as if it were head-to-head evidence. VEPPANU’s distinct mechanism and favorable discontinuation rate are useful positioning points; access, testing, physician sequencing and safety monitoring will determine share.

The label warns about QTc prolongation and embryo-fetal toxicity. ECG and electrolyte monitoring, CYP3A interactions and drugs that prolong QT can affect real-world convenience. Serious adverse reactions occurred in 9% and permanent discontinuation due to an adverse reaction in 2.9% in the label dataset.

Pipeline optionality around the brand should be valued cautiously. Before Rigel licensed VEPPANU, Arvinas and Pfizer removed two large Phase 3 combination programs from their 2025 development plan. Rigel has ongoing transition and development obligations, but it has not guided to a near-term combination readout; the investable 2026 question is the approved monotherapy launch.

09 R289: early signal, small sample, meaningful 2026 readout

R289 is an oral prodrug of R835, a selective dual inhibitor of IRAK1 and IRAK4. The biological thesis is that suppressing dysregulated innate-immune signaling in the marrow may reduce the inflammatory environment associated with persistent cytopenias in lower-risk MDS.

As of the October 28, 2025 cutoff, the dose-escalation study had enrolled 33 heavily pretreated patients with a median age of 75 and a median of three prior therapies. Among 18 evaluable transfusion-dependent patients receiving at least 500 mg once daily, six, or 33%, achieved red-blood-cell transfusion independence lasting more than eight weeks. Four lasted more than 16 weeks and three more than 24 weeks; median duration was 22.9 weeks.

The dataset is encouraging but fragile. It is open-label, non-randomized and small. Dose cohorts contain only a handful of evaluable patients. Rigel also disclosed that one earlier minor HI-E responder was reclassified as a non-responder after previously uncaptured transfusions were identified. That correction does not invalidate the later six-of-18 RBC-TI result, but it raises the evidence-discipline bar for the expansion dataset. The most frequent Grade 3/4 events included anemia, neutrophil decrease and pneumonia. One dose-limiting toxicity involving Grade 4 AST and Grade 3 ALT elevation occurred at 750 mg.

The expansion phase randomizes up to 40 transfusion-dependent patients between 500 mg once daily and twice daily. That design should help choose a Phase 2 dose, but it is not a registrational efficacy trial. Constructive data would reproduce clinically durable transfusion independence across a broader cohort without a dose-limiting liver or infection pattern. A weak expansion would reduce the value of Rigel’s main proprietary pipeline asset even if the commercial business remains profitable.

10 Partnerships, returned rights and portfolio optionality

Rigel’s external relationships create diversified cash flows but complicate accounting. Grifols contributes fostamatinib supply and royalties. Kissei has fostamatinib and olutasidenib rights in defined Asian territories. Medison and Knight cover additional markets. Milestones can make contract revenue lumpy; supply and royalty income is more repeatable but depends on partner execution.

The Lilly agreement is the clearest example of why optionality should not be capitalized prematurely. Rigel received a $125 million upfront payment in 2021 for ocadusertib and once had access to hundreds of millions in potential milestones. Lilly terminated the agreement effective June 15, 2026; rights reverted and Rigel no longer expects Lilly milestones or royalties. The rheumatoid-arthritis Phase 2 study completed primary data collection, but no result has been disclosed publicly. Termination after Phase 2 is an adverse strategic read-through, not proof that the trial failed. The returned program may retain scientific value, but no funded development plan has been established publicly.

Partnered development of olutasidenib broadens the evidence base at modest direct cost relative to fully sponsored registrational programs. However, positive investigator-sponsored data do not automatically expand the label or revenue. Each new indication still requires an adequate regulatory package and commercial justification.

11 Balance sheet, debt, dilution and hidden commitments

Rigel generated $33.4 million of operating cash in H1, then allocated capital to acquired rights: $70.3 million of intangible-asset payments, $55.3 million to repay the prior term loan and fees, a $40 million revolver draw, and a $5 million final GAVRETO payment. The apparent fall from $155.0 million of year-end liquidity to $95.3 million at June is therefore primarily a portfolio-acquisition and financing event, not an operating cash burn.

Equity dilution still deserves monitoring. At June 30 there were 3.351 million options and 0.973 million RSUs outstanding, though not all are currently dilutive. Another 1.182 million shares were available for future equity-plan grants and 0.396 million for the employee purchase plan. H1 stock-based compensation was $10.3 million. The 2026 proxy showed 30.6% share-plan overhang at year-end 2025 under its defined methodology.

The ATM and shelf provide flexibility. They are not current dilution: the company stated that no ATM shares had been sold through June 30. They do mean capital can be raised if management pursues more business development or working-capital needs rise.

Contractual commitments extend beyond balance-sheet debt. In addition to VEPPANU’s approximately $26.8 million take-or-pay supply obligation, Rigel disclosed roughly $16.3 million of TAVALISSE manufacturing commitments, including about $2.5 million for the remainder of 2026 and $9.5 million across 2027–2028. These obligations do not contradict management’s 12-month liquidity statement, but they reduce the usefulness of headline net cash as a stand-alone measure of financial flexibility.

12 Management, governance and ownership

Raul Rodriguez has been chief executive since November 2014 and has worked at Rigel since 2000. Dean Schorno has been CFO since 2018. David Santos, chief commercial officer since 2020, brings prior hematology/oncology launch experience from Jazz, Medivation, Onyx and Genentech. Joseph Lasaga leads business development and portfolio strategy.

Alison Hannah became chief medical officer in July 2026 and resigned from the board in connection with the appointment. Her oncology-development and regulatory experience is relevant as Rigel takes responsibility for VEPPANU and chooses the next R289 development path. The transition also means the R289 year-end readout will be one of the first visible tests under the new CMO.

These are dated beneficial-ownership snapshots with different reporting dates and denominators; they should not be summed into a current institutional-ownership total. The proxy also listed CEO Raul Rodriguez at 5.97% beneficial ownership, but 844,666 of his 1,094,485 reported shares were options exercisable within 60 days, not the same as cash common-stock ownership.

Recent Form 4 activity should be interpreted transaction by transaction. H1 disclosures include option exercises, RSU releases and tax-withholding dispositions; those are compensation mechanics, not automatically discretionary market selling. Director Kamil Ali-Jackson had a pre-existing Rule 10b5-1 plan permitting sales. No broad pattern of open-market insider buying is established by the filings reviewed.

The governance concern is compensation dilution rather than insider control. Outstanding awards and future plan capacity are material relative to an 18.7 million basic share base, so per-share progress should be measured with diluted shares and stock-based compensation visible.

13 Competitive landscape by franchise

Rigel’s portfolio is differentiated by mechanism, not protected from competition. Each product is used in a specialist setting where label detail, sequencing, payer access, adverse-event management and physician familiarity can matter as much as headline efficacy.

14 Market data, analysts and positioning

Rigel’s investor-relations page lists five covering firms: Cantor Fitzgerald, Citigroup, H.C. Wainwright, Jefferies and Piper Sandler. Rigel does not publish their current ratings or targets, and consensus snapshots carrying different dates are not blended together here. The relevant point is that coverage exists but is still a small sample.

Short interest is high enough to amplify moves in either direction. Nasdaq-reported short interest was 3.157 million shares at the July 15 settlement date. Percent-of-float estimates differ because data vendors use different float counts; treating the exact share figure and settlement date as primary avoids false precision.

The quoted trailing P/E is misleadingly low because 2025 net income included a $245.9 million deferred tax benefit. A cleaner market lens uses enterprise value against recurring product sales and normalized operating earnings, while deducting the economics of licensed products.

15 Retail sentiment

The live Stocktwits stream is useful as an attention gauge, not research. At the August 10 review, the public sentiment page did not expose a current numerical sentiment or message-volume score; no percentages have been invented to fill the template.

16 Valuation framework: use a hybrid, not a headline P/E

At the August 27, 2026 close, an illustrative diluted-basis enterprise value is about $862 million. That equals roughly 2.6 times the $285–295 million 2026 total-revenue guide. Against the $255–265 million product-sales guide, the multiple is roughly 2.8–2.9 times. Those are orientation points, not a target price.

A single sales multiple misses asset quality. TAVALISSE has the strongest current economics but a disclosed 2032 generic path. REZLIDHIA and GAVRETO are acquired assets with milestones and royalties. VEPPANU carries the heaviest royalty and transition stack and has not yet generated Rigel revenue. R289 is early clinical optionality that should be probability-weighted, not valued as an approved product.

The deferred tax asset also matters. Rigel recognized a large 2025 tax benefit and carried a $238.1 million deferred tax asset at June 30. It can shelter future taxable income if realized, but it is not cash and should not be added dollar-for-dollar to enterprise value.

17 Catalyst and execution timeline

A month-only entry in a clinical-trial registry is not a confirmed catalyst date. Company guidance is therefore the reference for R289 and marks the absence of an exact day, rather than converting an estimated registry date into a false deadline.

18 Bull case, bear case and thesis falsifiers

What bulls see

• A profitable commercial platform: $67.0 million of Q2 product sales, $23.6 million of operating income and positive H1 operating cash flow reduce classic biotech financing dependence.
• Two growing core brands: TAVALISSE grew 18% and REZLIDHIA 27% in Q2.
• Guidance excludes the new launch: any material 2026 VEPPANU revenue is incremental to the stated sales range, though launch costs are incremental too.
• R289 creates internal upside: 33% transfusion independence in early evaluable active-dose patients is enough to justify the expansion readout.
• International optionality: Brazil approval, Mexico launch and Japan olutasidenib filing broaden the portfolio without building a full direct global infrastructure.
• Elevated short interest: positive launch or clinical surprises can produce sharp covering moves in a relatively small float.

What bears see

• Concentration: TAVALISSE still supplies about 71% of product sales and has a disclosed 2032 generic pathway.
• License economics: VEPPANU carries mid-teens to mid-twenties royalties, up to $320 million of regulatory/commercial milestones and additional funding/supply obligations.
• GAVRETO weakness: Q2 volume declined and the boxed infection warning complicates competition with Retevmo.
• Early clinical risk: R289 efficacy rests on a small, uncontrolled dataset; expansion can fail to reproduce it.
• Diluted ownership: 3.35 million options, 0.97 million RSUs and more grant capacity are meaningful beside 18.68 million basic shares.
• Accounting opticals: the low trailing P/E and prior-year EPS are distorted by a large deferred tax benefit and a non-cash Lilly release.
• Commercial bandwidth: a small company must launch into breast cancer while maintaining three specialist brands and funding multiple programs.

19 Scenario framework

20 Quarterly monitoring checklist

21 Merlintrader bottom line

Rigel enters the second half of 2026 with a stronger operating foundation than many companies of similar biotech market value. Three marketed products generated $121.9 million of H1 sales, operating cash flow was positive, the company raised revenue guidance and management still expects full-year profit. Those are verified fundamentals, not a development-stage narrative.

The next layer is more demanding. VEPPANU gives Rigel a differentiated approved breast-cancer asset and an immediate fourth brand, but the license transfers much of the upside economics back to Arvinas and Pfizer through royalties, milestones and funding obligations. R289 offers proprietary clinical upside, but its early signal comes from too few patients to support confident probability assumptions.

The cleanest thesis is therefore not “cheap because the P/E is 2.” The clean thesis is that a cash-generating TAVALISSE-led base can finance a portfolio transition, while REZLIDHIA, VEPPANU and eventually R289 reduce concentration before the 2032 generic pathway matters. The cleanest bear case is that Rigel grows revenue by buying expensive assets faster than it grows contribution profit per diluted share.

The next scorecards are explicit: VEPPANU net sales in the third-quarter report, after commercial availability began on August 13; R289 dose selection in the second half; preliminary R289 expansion data by year-end; and each quarterly report’s product volume, cash conversion and diluted share count.

Related research on Merlintrader

• Rigel Pharmaceuticals deep dive after the Lilly partnership termination — earlier background on the ocadusertib rights return.
• Biotech Stocks Hub 2026 — the full index of company hubs and biotech research.
• Free Biotech Catalyst Calendar — FDA, PDUFA and clinical-event tracking.
• Biotech Catalyst Trading Guide — how to separate event timing from evidence and valuation.